stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) EV/FCF
As of 5 November 2026, Aurinia Pharmaceuticals Inc (AUPH) trades at a EV/FCF of 9.7×. Over the past ten years it has ranged from −422× (September 2024) to 42.8× (December 2024); the current reading is higher than 81% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 13.3× | (40.54%) |
| FY2024 | 22.3× | — |
| FY2023 | −28.6× | — |
| FY2022 | −5.7× | — |
| FY2021 | −15.8× | — |
| FY2020 | −16.5× | — |
| FY2019 | −24.8× | — |
| FY2018 | −8.8× | — |
| FY2017 | −4.8× | — |
| FY2016 | 2.9× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 9.7× | (6.28%) |
| Jun 2026 | 10.3× | 5.52% |
| Mar 2026 | 9.8× | (26.26%) |
| Dec 2025 | 13.3× | 37.13% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| IMNM Immunome, Inc. compare | −7.0× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.6× |
| AUPH Aurinia Pharmaceuticals Inc | 9.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on AUPH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement